CDKN2A and malignant peripheral nerve sheath tumor: Owing to the strong association with NF1 loss, most preclinical MPNST models have been developed in NF1-deficient systems, either alone or combined with conditional deletion of additional tumor suppressors such as Tp53 (also known as Trp53) or Cdkn2a (Mohamad et al., 2021).